NCT02571166View on ClinicalTrials.gov

HSV529 Vaccine in HSV-2 Seropositive Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions
Herpes Simplex Virus 2
Interventions
BIOLOGICAL

HSV529

Live, Replication-defective HSV-2 virus

DRUG

Valacyclovir

500 mg orally, once daily for 4 weeks

Trial Locations (1)

98104

University of Washington Virology Research Clinic, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT02571166 - HSV529 Vaccine in HSV-2 Seropositive Adults | Biotech Hunter | Biotech Hunter